Sialyltransferase family members and cervix squamous cell carcinoma

Sialic acids including a number of their derivatives are ubiquitous at the terminal positions of the oligosaccharides of glycoproteins. The transfer of sialic acids from cystidine-5-monophospho-N-acetylneuraminic acid (CMP-NeuAc) to the terminal position of the carbohydrate group of glycoproteins and glycolipids is catalyzed by a family of sialyltransferases (STs). There is a large body of evidence to suggest that tumor cells have altered surface properties from their normal counterparts, and that these changes are partially due to altered sialo-glycoconjugates expressed on the plasma membrane and that altered sialylation (change in glycoprotein expression), which occurs during certain pathological processes, such as oncogenic transformation, tumor metastases, and invasion, is associated with enhanced ST activity. In this report we attempt to review the important findings in studing sialyltransferases of cervix squamous cell carcinoma.

Prognosis; Sialyltransferase; Squamous cell carcinoma of the cervix

[1] Fukuda M.: "Cell surface carbohydrates: cell-type specific expression". In: Fukuda M., Hindsgaul 0., editors. Molecular Glycobiology. Oxford: Oxford University Press; 1994, 1.

[2] Thomas P.: "Cell surface sialic acid as a mediator of metastatic potential in colorectal cancer". Cancer J., 1996, 9, 1.

[3] Petretti T., Kemmner W., Schulze B., Schlag P.M.: "Altered mRNA expression of glycosyltransferase in human colorectal carcinornas and liver metastases". Gut., 200, 46, 359.

[4] Lowe J.B.: "Carbohydrate recognition in cell-cell interaction". In Fukuda M., Hindsgaul 0., editors. Molecular Glycobiology. Oxford, Oxford University Press, 1994, 163.

[5] Schauer R.: "Sialic acids and their role as biological masks". Trends Biochem. Sci., 1985, 10, 357.

[6] Kirn Y. J., Kirn K. S., Kim S. H., Kirn C.H., Ko J. H., Choe I. S., et al.: "Molecular cloning and expression of human Gal β1 3Ga1Nac a2,3-sialyltransferase (hST3GalII)". Bioch. Biophy Res. Com., 1996, 228, 324.

[7] Fukuda M.: "Possible roles of turnor-associated carbohydrate antigens". Cancer Res., 1996, 56, 2237.

[8] Hakomori S.: "Turnor malignancy defined by aberrant glycosylation and shingo-(glyco)-lipid rnetabolism". Cancer Res., 1996, 56, 5309.

[9] Dorudi S., Kinrade E., Marshall N. C., Feakins R., Williarns N. S., Bustin S. A.: "Genetic detection of lyrnph node micrometastases in patients with colorectal cancer". Br. J. Surg., 1998, 85, 98.

[10] Aubert M., Panicot L., Crotte C., Gibier P., Lornbardo D., Sadoulet M. O., Mas E.: "Restoration of a (1,2) fucosyltransferase activity decreases adhesive and rnetastatic properties of human pancreatic cancer cells". Cancer Res., 2000, 60, 1449.

[11] Zhu Y., Srivatana U., Ullah A., Gagneja H., Berenson C. S., Lance P.: "Suppression of a sialyltransferase by antisense DNA reduces invasiveness of hurnan colon cancer cells in vitro." Biochem Biophys. Acta, 2001, 1536, 148.

[12] Yamamoto H., Oviedo A., Sweeley C., Saito T., Moskal J.R.: "a 2,6-sialylation of cell-surface N-glycans inhibits gliorna forrnation in vivo". Cancer Res., 2001, 61, 6822.

[13] Schneider F.. Kernrnner W., Haensch W., Franke G., Gretschel S., Karsten U., Schlag P. M.: "Overexpression of sialyltransferase CMP-sialic acid: Gal β l ,3GalNAc-R a6-Sialyltransferase is related to poor patient survival in hurnan colorectal carcinornas" Cancer Res., 2001, 61, 4605.

[14] Wang P.H., Lo W. L., Hsu C. C., Lin T. W., Lee W. L., Wu C. Y., Yuan C. C., Tsai Y. C.: "Different enzyrne activities of sialyltransferases in gynecological cancer cell lines". Eur. J. Gynaecol. Oneal., 2002, 23, 221.

[15] Wang P.H., Li Y. F., Juang C. M., Lee Y. R., Chao H. T., Tsai Y. C., Yuan C. C.: "Altered rnRNA expression of sialyltransferase in squarnous cell carcinomas of the cervix". Gynecol. Oneal., 2001, 83, 121.

[16] Wang P. H., Li Y. F., Juang C. M., Lee Y. R., Chao H. T., Ng H. T., et al.: "Expression of sialyltransferase family members in cervical squamous cell carcinoma correlates with lymph node metastases". Gynecol. Oncol., 2002, in press.

[17] Wu C. Y., Hsu C. C., Chen S. T., Tsai Y. C.: "Soyasaponin I, a potent and specific sialyltransferase inhibitor". Biochem. Biophy. Res. Communic., 2001, 284, 466.

[18] Recchi M. A., Hebbar M., Hornez L., Harduin-Lepers A., Peyrat J.P., Delannoy P.: "Multiplex reverse transcription polymerase chain reaction assessment of sialyltransferase expression in human breast cancer". Cancer Res., 1998, 58, 4066.

[19] Recchi M. A., Harduin-Lepers A., Boilly-Marer Y., Verbert A., Delannoy P.: "Multiplex RT-PCR method for the analysis of the expression of human sialyltransferase: application to breast cancer cells". Glycoconj. J., 1998, 15, 19.

[20] Brockhausen I ., Yang J., Lehotay M., Ogata S., Itzkowitz S.: "Pathways of mucin 0-glycosylation in normal and malignant rat colonic epithelial cells reveal a mechanism for cancer-associated Sialyl-Tn antigen expression". Biol. Chem., 2001, 382, 219.

[21] Kannagi R.: "Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer". Glycoconj. J., 1997, 14, 577.

[22] Harduin-Lepers A., Recchi M.A., Delannoy P.: "1994, the years of sialyltransferase". Glycobiology, 1995, 5, 741.

[23] Tsuji S.: "Molecular cloning and functional analysis of sialyltransferases". J. Biochem. (Tokyo), 1996, 120, I.

[24] Itzkowitz S. H., Yuan M., Montgomery C. K., Kjeldsen T., Takahashi H. K., Bigbee W. L., Kim Y. S.: "Expression of Tn, sialosyl-Tn, and T antigens inhuman colon cancer". Cancer Res., 1989, 49, 197.

[25] Ura Y., Dion A. S., Williams C. J., Olsen B. D ., Redfield E. S., Ishida M., et al.: "Quantitative dot blot analyses of blood-grouprelated antigens in paired normal and malignant human breast tissues". Int. J. Cancer, 1992, 50, 57.

[26] Burchell J., Poulsom R., Hanby A., Whitehouse C., Cooper L., Clausen H., Miles D., Taylor-Papadimitriou J.: "An a2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas". Glycobiology, 1999, 9, 1307.

[27] Matsuura N., Narita T., Hiraiwa N ., Hiraiwa M., Murai H., Iwase T., et al.: "Gene expression of fucosyl- and sialyl-trans ferases which synthesize sialyl Lewisx, the carbohydrate ligands for Eselectin, in human breast cancer". Int. J. Oncol., 1998, 12, 1157.

[28] Ito H., Hiraiwa N., Sawada-Kasugai M., Akamatsu S., Tachikawa T., Kasai Y., et al.: "Altered mRNA expression of specific molecular species of fucosyl- and sialyl-transferases in human colorectal cancer tissues". Int. J. Cancer, 1997, 71, 556.

[29] Yamada N ., Chung Y. S., Takatsuka S., Arimota Y., Sawada T., Dohi T., Sowa M.: "Increased sialyl sialyl Lewis a expression and fucosyltransferase activity with acquisition of a high metastatic capacity in a colon cancer cell line". Br. J. Cancer, 1997, 76, 582.

[30] Kudo T., Ikehara Y., Togayachi A., Morosumi K ., Watanabe M., Nakamura M., et al.: "Up-regulation of a set of glycosyltransferase genes in human colorectal cancer". Lab. Invest., 1998, 78, 797.

[31] Dall'Olio F. D., Chiricolo M., Lau J. T. Y.: "Differential expression of the hepatic transcript of 􀃭-galactoside a2,6 sialyltransferase in human colon cancer cell lines". Int. J. Cancer, 1999, 81, 243.

[32] Bosch J., Brossmer R., Kemmner W., Schlag P.: "Preparation and characterization of differently aggregated colorectal carcinoma cell subpopulations from surgical specimens". Cancer Detection Prevention, 1998, 22, 319.

[33] Ogawa J. I., Inoue H., Koide S.: "a-2,3-sialyltransferase type 3N and a-1, 3-focosyltransferase type VII are related to sialyl Lewis synthesis and patient survival from lung carcinoma". Cancer, 1997, 79, 1678.

[34] Ogawa J., Tsurumi T., Yamada S., Koide S., Shohtsu A.: "Blood vessel invasion and expression of sialyl Lewis and proliferation cell nuclear antigen in stage I non-small cell lung cancer". Cancer, 1993, 73, 1177.

[35] Pousset D., Piller V., Bureaud N., Monsigny M., Piller F.: "Increased a-2, 6 sialylation of N-Glycans in a transgenic mouse model of hepatocellular carcinoma". Cancer Res., 1997, 57, 4249.

[36] Liu F., Qi H. L., Chen H. L.: "Regulatii on of differentiation and proliferation-inducer on lewis antigens, a-fucosyltransferase and metatstic potential in hepatocarcinoma cells". Br. J. Cancer, 2001, 84, 1556.

[37] Petretti T., Schulze B ., Schlag P. M., Kemmner W.: "Altered mRNA expression of glycosyltransferases in human gastric carcinomas". Bioch. Biophy. Acta, 1999, 1428, 209.

[38] Bergler W., Riedel F., Schwartz-Albiez R., Gross H. J., Hormann K .: "A new histobiochemical method to analyze sialylation on cell-surface glycoproteins of head and neck squamous-cell carcinomas". Eur. Arch. Oto-Rhino-Laryngol., 1997, 254, 437.

[39] Yamamoto H., Saito T., Kaneko Y., Kersey D., Yong V. W., Bremer E. G ., et al.: "a 2, 3-sialyltransferase mRNA and a 2, 3-linked glycoprotein sialylation are increased in malignant gliomas". Brain Res., 1997, 755, 175.

[40] Kaneko Y., Yamamoto H., Kersey D. S., Colley K. J., Leestma J. E., Moskal J. R.: "The expression of Gal β l ,4GlcNAc a 2, 6 sialyltransferase and a 2,6-linked sialoglycoconjugates in human brain tumors". Acta Neuropathologica, 1996, 91, 284.

[41] Fukushima K ., Hara-Kuge S., Seko A., Ikehara Y., Yamashita K .: "Elevation of a 2➔6 sialyltransferase and a 1今2 fucosyltransferase activities in human choriocarcinoma". Cancer Res., 1998, 58, 4301.

[42] Okajima T., Fukumoto S., Miyazaki H., Ishida H., Kiso M., Furnkawa K ., et al.: "Molecular cloning of a novel a 2, 3-sialyltransferase(ST3Gal IV) that sialylates type II lactosamine structures on glycoproteins and glycolipids". J. Biol. Chem., 1999, 274, 11479.

[43] Lee Y.C., Kjima N., Wada E., Kurosawa N., Nakaoka T., Hamamoto T., Tsuji S.: "Cloning and expression of cDNA for a new type of Galβ I, 3GalNAc a 2, 3-sialyltransferase". J. Biol. Chem., 1994, 269, 10028.

[44] Kurosawa N ., Kojima N ., Inoue M., Hamamoto T., Tsuji S.: "Cloning and expression of Gal β 1, 3GalNAc-specific GalNAc a 2, 6-sialyltransferase". J. Biol. Chem., 1994, 269, 19048.

[45] Kurosawa N ., Hamamoto T., Lee Y. C., Nakaoka T., Kojima N ., Tsuji S.: "Molecular cloning and expression of GalNAc a 2, 6- sialyltransferase". J. Biol. Chem., 1994, 269, 1402.

[46] Taniguchi A., Kaneta R., Morishita K ., Matsumoto K .: "Gene structure a n d transcriptional regulation of human Gal β 1,4(3)GlcNAc a 2,3-sialyltransferase VI (hST3Gal VI) gene in prostate cancer cell line". Biochem. Biophy. Res. Communic., 2001, 287, 1148.

[47] Chang P. Y.: "Cancer Registry Annual Report". R.O .C. Taipei: Department of Health R.O.C., 1996.

[48] Yuan C. C., Wang P.H., Lai C. R., Yen M. S., Chen C. Y., Juang C. M.: "Prognosis-predicting system based on factors related to survival of cervical carcinoma". Int. J. Gynecol. Obstet., 1998, 63, 163.

[49] Yuan C.C., Wang P.H., Lai C.R., Tsu E.J., Yen M.S., Ng H.T.: "Recurrence and survival analyses of 1,115 cervical cancer patients treated with radical hysterectomy". Gynecol . Obstet . Invest., 1999, 47, 127.

[50] Yuan C. C., Wang P. H., Ng H. T., Li Y. F., Huang T. S., Chen C. Y., et al.: "Detecting cytokeratin 19 mRNA in the peripheral blood cells of cervical cancer patients and its clinical-pathological correlation". Gynecol. Oneal., 2002, 85, 148.

[51] Yuan C. C., Wang P.H., Ng H. T., Tsai L. C., Juang C. M., Chm L. M.: "Both TPA and SCC-Ag levels are prognostic even in high risk stage IB-Ila cervical carcinoma determined by a stratification analysis". Euro. J. Gynaecol. Oneal., 2002, 23, 17.

[52] Juan C. M., Wang P. H., Yen M. S., Lai C. R., Ng H. T., Yuan C C.: "Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage 1B and IIA squamous cell carcinoma of the uterine cervix". Gynecol. Oneal., 2000, 76, 103.

[53] Chao H. T., Wang P. H., Tseng J. Y., Lai C. R., Chiang S. C., Yuan C. C.: "Lymphocyte infiltrated on FIGO stage IIB squamous cell carcinoma of the cervix is a prominent factor for disease-free survival". Euro. J. Gynaecol. Oneal., 1999, 20, 136.

[54] Loh T. 0., Wang P. H., Yen M. S., Chao K. C., Ng H. T., Yuan C. C.: "Identifying local tumor variables for operable node-negative, margin-free patients with bulky cervical carcinoma of FIGO stage IB, IIA and IIB without adjuvant therapies". Euro. J. Gynaecol. Oneal., 2001, 22, 420.

[55] Yuan C. C., Ng H. T., Wang P. H.: "New strategies and advances in the management of cervical carcinoma". Gan To Kagaku Ryoho, 2002, 29 (Suppl. 1), 143.

[56] Wolf J. K ., Ramirez P. T.: "The molecular biology of cervical cancer". Cancer Invest., 2001, 19, 621.

[57] Schindl M., Oberhuber G., Obermair A., Schoppmann S. F., Karner B., Birner P.: "Overexpression of Id-I protein is a marker for unfavorable prognosis in early-stage cervical cancer". Cancer Res., 2001, 61, 5703.

[58] Wei L. H., Kuo M. L., Chen C. A., Cheng W. F., Cheng S. P., Hsieh F. J., Hsieh C. Y.: "Interleukin-6 in cervical cancer: the relations hip with vascular endothelial growth factor". Gynecol. Oneal., 2001, 82, 49.

[59] Ueda M., Terai Y., Kumagai K., Ueki K., Yamaguchi H., Akise D., Ueki M.: "Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells". Gynecol. Oneal., 2001, 82, 162.

[60] Tjalma W. A., Weyler J. J.. Bogers J. J.. Pollefliet C., Baay M., Goovaerts G. C., et al.: "The importance of biological factors (bcl-2, bax, p53, PCNA, ML HPV and angiogenesis) in invasive cervical cancer". Euro. J. Obstet. Gynecol. Reprod. Biol., 2001, 97, 223.

[61] Ji M. Y., Lee Y. C., Kim K. S., Cho J. W., Jung K. Y., Kim C.H., Choo Y. K.: "Developmental patterns of Gal 􀃬 1,3(4)GlcNAc a 2,3-sialyltransferase (ST3Gal III) expression in the mouse: in situ hybridization using DIG-labeled RNA probes". Arch. Pharmacal. Res., 1999, 22, 243.

[62] Kannagi R.: "Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer". Glycoconj. J., 1997, 74, 577.

[63] Hakomori S. I.: "Tumor malignancy defined by aberrant glycosylation and sphingo) glycolipid metabolism". Cancer Res., 1996, 56, 5309.

[64] Phillips M. L., Nudelman E., Gaeta F. C. A., Perez M., Singhal A K., Hakomori S., Paulson J. C.: "ELAM-I mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Le'". Science, 1990, 250, 1130.

[65] Walz G., Aruffo A., Kolanus W., Bevilacqua M., Seed B.: "Recognition by ELAM-I of the sialyl-Le'determinant on myeloid and tumor cells". Science, 1990, 250, 1132.

[661 Kansas G. S.: "Selectins and their ligands: current concepts and controversies". Blood, 1996, 88, 3259.

[67] Takada A., Ohmori K., Yoneda T., Tsuyuoka K., Hasegawa K., Kiso M., Kannagi R.: "Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium". Cancer Res., 1993, 53, 354.